Recipharm completes a directed issue of 2.25 million Class

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Jan 26, 2016 at 2:30 AM

Recipharm completes a directed issue of 2.25 million Class B shares, raising proceeds of approximately SEK 276 million

NOT FOR DISTRIBUTION OR RELEASED, DIRECTLY OR INDIECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION, IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. Recipharm AB (publ) (“Recipharm”) has, based on the authorization granted by Recipharm’s Annual General Meeting on 7 May, 2015, resolved to carry out a direct share issue of 2,250,000 Class B shares at subscription price of SEK 122.50 per share (the “Issue”). The subscription price represents a discount of approximately 0.2 per cent compared to one week volume weighted average price prior to the Board of Directors’ resolution [1] , and a discount of approximately 0.8 per cent compared to the closing price on 25 January, 2016 [2]. Subscribers in the Issue are a few well known institutional investors. The reasons for deviation from the shareholders’ preferential rights is to diversify the shareholder base and at the same time raise capital in a time efficient manner to partly finance acquisition, previously announced during the fourth quarter 2015. Through the Issue, Recipharm will receive proceeds amounting to approximately SEK 275.6 million before transaction costs. The Issue entails a dilution of approximately 4.7 per cent of the capital in relation to the number of shares in Recipharm through an increase in the number of outstanding shares to 48,075,256 (divided into 12,685,716 shares of Class A and 35,389,540 shares of Class B). Carnegie Investment Bank AB (publ) has acted as financial advisor in connection with the transaction. For further information please visit www.recipharm.com or contact: Thomas Eldered, CEO, thomas.eldered@recipharm.com, telephone: +46 8 602 52 10 Björn Westberg, CFO, bjorn.westberg@recipharm.com, telephone: +46 8 602 46 20 This information is published in accordance with the Swedish Securities Market Act, the Swedish Financial Instruments Trading Act and/or the regulations of Nasdaq Stockholm. This information was submitted for publication on 26 January, 2016, at 08.00 am CET. Important information The release, announcement or distribution of this press release may in certain jurisdictions be restricted. The recipient of this press release is responsible for using the information in this press release in accordance with the applicable law in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Recipharm AB in any jurisdiction, neither of Recipharm AB or any other party. About Recipharm Recipharm is a leading CDMO company (Contract Development and Manufacturing Organisation) in the pharmaceutical industry based in Sweden employing some 2,500 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material including API and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from Big Pharma through to smaller research- and development companies. Recipharm’s turnover is approximately SEK 3.4 billion and the Company operates development and manufacturing facilities in Sweden, France, the UK, Germany, Spain, Italy and Portugal and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm. For more information on Recipharm and our services, please visit www.recipharm.com. [1] SEK 122.72 one week volume weighted average closing price prior to Board of Directors resolution. [2] SEK 123.50 closing price 25 January, 2016. Recipharm AB (publ) Corporate identity number 556498-8425 Address Lagervägen 7, SE-136 50 Jordbro, Sweden, Telephone 46 8 602 52 00, Fax 46 8 81 87 03 www.recipharm.com

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Intelligent Communication Forum Eyes Global Ecosystem Shift

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Webull Faces Class Action Suit: Key Deadlines Loom

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Novo's Semaglutide Shows Promise in MASH Study

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

ASTS Faces Class Action; Investors Beware of Pitfalls

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Quantum Space Joins $185M NASA Lunar Transport Deal

Quantum Space Bags a Chunk of NASA's Lunar Ambitions Alright, folks, buckle up because we're about to dive into the cosmos. Quantum Space just nabbed a sweet deal—a $185 million whopper of a contract from NASA's Moon Base Transportation program. This isn't chump change; it's a 25% slice for Quantum from the lot Arrow Science and Technology is heading. We're talking...

Amplifon Data Breach Spurs Legal Scrutiny for Millions

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Allergan Aesthetics Study Shows Rising Patient Satisfaction

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

MWC26 Doha: Bridging Standards for MENA's Future

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...